New drug trial offers hope for rare, overactive immune disease

This study tested whether a drug called itacitinib could help adults with a non-severe form of hemophagocytic lymphohistiocytosis (HLH), a rare and serious condition where the immune system becomes dangerously overactive. The goal was to see if itacitinib could control the disease effectively, potentially with fewer side effects than standard steroid treatments. The trial involved 35 adult patients and measured their response to the drug over 15 days.